Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: FibroBiologics, Inc.

Market Cap 5.2M 4.5M 4.14M 3.88M 7.27M 495M 7.38M 48.91M 19.07M 241M 19.53M 19.12M 834M P/E Ratio 2026 *
-0.97x
P/E Ratio 2027 * -0.44x
Enterprise Value 5.2M 4.5M 4.14M 3.88M 7.27M 495M 7.38M 48.91M 19.07M 241M 19.53M 19.12M 834M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day-3.42%
1 week-9.61%
Current month-19.74%
1 month-15.36%
3 months-86.31%
6 months-88.15%
Current year-79.30%
1 week 0.91
Extreme 0.91
1.04
1 month 0.91
Extreme 0.91
1.2
Current year 0.91
Extreme 0.91
9.6
1 year 0.91
Extreme 0.91
17.2
3 years 0.91
Extreme 0.91
1,100
5 years 0.91
Extreme 0.91
1,100
10 years 0.91
Extreme 0.91
1,100
Manager TitleAgeSince
Chief Executive Officer 62 2021-04-07
Director of Finance/CFO 53 2025-06-08
Chief Tech/Sci/R&D Officer 57 2021-07-31
Director TitleAgeSince
Director/Board Member 60 2021-04-07
Chairman 62 2021-04-07
Director/Board Member 51 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
05-03Free

Chief Financial Officer

61,607 1.7538%
05-03Free

Chief Executive Officer

92,410 2.6306%
05-03Free

General Counsel

61,607 1.7538%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%-9.61%-94.66% - 5.2M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+2.79%-13.71%-17.53% 22.64B
+1.17%+3.85%+1.00%+401.79% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+0.82%+27.17%+178.31% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.28%-0.76%+16.53%+108.52% 20.99B
Weighted average by Cap. +1.71%+1.60%+33.72%+101.64%

Financials

2026 *2027 *
Net sales - -
Net income -20.36M -17.58M -16.2M -15.17M -28.42M -1.93B -28.86M -191M -74.59M -942M -76.4M -74.77M -3.26B -24.01M -20.74M -19.11M -17.89M -33.53M -2.28B -34.04M -226M -87.98M -1.11B -90.12M -88.2M -3.85B
Net Debt - -
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Employees
15
Date Price Change Volume
26-06-12 0.9310 $ -3.42% 236,308
26-06-11 0.9640 $ +1.06% 53,423
26-06-10 0.9539 $ +2.57% 108,434
26-06-09 0.9300 $ -7.92% 136,826
26-06-08 1.010 $ -1.94% 74,371
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9640USD
Average target price
13.50USD
Spread / Average Target
+1,300.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBLG Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!